Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease

Clinical Site, Innsbruck

Clinical Site, Klagenfurt

Clinical Site, Sankt Pölten

Clinical Site, Sankt Veit an der Glan

Clinical Site, Vienna

Clinical Site, Berlin

Clinical Site, Hamburg

Clinical Site, Kiel

Clinical Site, Landshut

Clinical Site, Ulm

Clinical Site2, Budapest

Clinical Site, Budapest

Clinical Site, Miskolc

Clinical Site, Mosonmagyaróvár

Clinical Site, Bydgoszcz

Clinical Site2, Krakow

Clinical Site, Krakow

Clinical Site, Lodz

Clinical Site, Piotrkow Trybunalski

Clinical Site, Warsaw

Clinical Site2, Wroclaw

Clinical site, Wroclaw

Clinical site, Kemerovo

Clinical Site, Krasnoyarsk

Clinical Site2, Moscow

Clinical Site, Moscow

Clinical Site, Penza

Clinical site, Rostov-on-Don

Clinical Site, Saint Petersburg

Clinical Site2, Samara

Clinical Site, Samara

Clinical Site, Tomsk

ClinicaL Site, Córdoba

Clinical Site, Girona

Clinical Site 2, Madrid

Clinical Site, Madrid

Clinical Site, Kharkiv

Clinical site, Khmelnytskyi

Clinical Site 3, Kyiv

Clinical Site2, Kyiv

Clinical Site, Kyiv

Clinical Site2, Lviv

Clinical Site, Lviv

Clinical Site, Odesa

Clinical Site, Ternopil

Clinical Site2, Vinnytsia

Clinical Site3, Vinnytsia

Clinical Site, Vinnytsia

Clinical Site2, Zaporizhzhya

Clinical Site3, Zaporizhzhya

Clinical Site, Zaporizhzhya